VOLUME 11 NUMBER 4 • NOVEMBER 2014
143
SA JOURNAL OF DIABETES & VASCULAR DISEASE
REVIEW
as are seen in hypertensive emergencies. Ideally, all patients with
hypertensive urgency should be treated in hospital.
Commence treatment with two oral agents and aim to lower the
diastolic BP to 100 mmHg slowly over 48 to 72 hours. This BP lowering
can be achieved with the use of: (1) long-acting CCBs; (2) ACEI, initially
used in very low doses, but avoid if there is severe hyponatraemia
(serum Na < 130 mmol/l indicates hyper-reninaemia and BP may fall
dramatically with ACEI); (3)
β
- blockers; and (4) diuretics.
• Hypertensive emergency
A hypertensive emergency is severe, often acute elevation of BP
associated with acute and ongoing organ damage to the kidneys,
brain, heart, eyes (grade 3 or 4 retinopathy) or vascular system.
These patients need rapid (within minutes to a few hours) lowering
of BP to safe levels. Hospitalisation is ideally in an intensive care unit
(ICU) with experienced staff and modern facilities for monitoring.
If an ICU is unavailable, the patient may be closely monitored and
treated in the ward.
Intravenous antihypertensive therapy, tailored to the specific
type of emergency, has become the standard of care. Labetalol,
nitroprusside or nitroglycerin are the preferred intravenous agents.
Overzealous lowering of BP may result in stroke. A 25% reduction
in BP is recommended in the first 24 hours. Oral therapy is instituted
once the BP is more stable. Although most adult patients with a
hypertensive emergency will have BP > 220/130 mmHg, it may
also be seen at modest BP elevations; for example, in a previously
normotensive woman during pregnancy (eclampsia) or in the
setting of acute glomerulonephritis, especially in children.
Severe HTN associated with ischaemic stroke and intracerebral
haemorrhageshouldbemanagedaccordingtotherecommendations
of the Neurological Association of South Africa.
26
Great caution
should be exercised in lowering BP after an ischaemic stroke due to
the risk of extending the ischaemic penumbra.
Resistant hypertension
HTN that remains > 140/90 mmHg despite the use of three
antihypertensive drugs in a rational combination at full doses and
including a diuretic (hydrochlorothiazide 25 mg or indapamide
2.5 mg) is known as resistant HTN. Common causes of resistant
HTN are listed in Table 8.
The therapeutic plan must include measures to ensure adherence
to therapy and lifestyle changes. Unsuspected causes of secondary
HTN are less common, but need to be considered based on history,
examination and special investigations. It is essential to exclude
pseudo-resistance by performing SBPM or 24-hour ABPM. Referral
to a specialist is often indicated for a patient with resistant HTN.
Once the issues relating to lifestyle, adherence to therapy, white
coating, etc. outlined in Table 7 have been satisfactorily managed,
then consideration should be given to the addition of the fourth-
and fifth-line drug. Currently spironolactone (25–50 mg only) with
careful monitoring of serum potassium, beta-blockers and/or long-
acting doxazasin is recommended.
27,28
Other choices include direct-
acting vasodilators (hydralazine, minoxidil), or centrally acting drugs
(methyldopa, moxonidine, reserpine).
Initial studies of renal denervation in patients with resistant HTN
showed very promising results.
29,30
The recent publication of the
Simplicity 3 study showing no significant effect on BP compared
to sham procedure, the place of renal denervation in the treatment
of resistant HTN remains to be established and is not supported by
this guideline.
31
Special considerations for hypertension in certain
populations
Blacks and Asians
Blacks are more prone to complications of stroke, heart failure and
renal failure, while the incidence of coronary heart disease, although
increasing in frequency, is less common compared with that in whites
and Asians.
32
The prevalence of diabetes mellitus and the metabolic
syndrome is higher in Asians compared to other racial groups.
33
Compared to whites, blacks respond poorly to ACEI and
β
-blockers as monotherapy, but this difference disappears once
these drugs are combined with diuretics. Overall, CCBs show the
most consistent response in blacks compared to other classes of
drugs used as monotherapy.
23,34
However there is a higher incidence
of angioedema in blacks treated with an ACEI.
35
Hypertension in children and adolescents
36,37
HTN in children is an important issue beyond the scope of this
guideline. In adolescents, the HTN is increasingly linked to obesity
and affects up to 10% of people between the ages of 15 and
Table 8.
Causes of resistant hypertension in South Africa
Non-adherence
to therapy
• Instructions not understood
• Side effects
• Cost of medication and/or cost of attending at
healthcare centre
• Lack of consistent and continuous primary care
• Inconvenient and chaotic dosing schedules
• Organic brain syndrome (e.g. memory deficit)
Volume overload • Excess salt intake
• Inadequate diuretic therapy
• Progressive renal damage (nephrosclerosis)
Associated
conditions
• Smoking
• Increasing obesity
• Sleep apnoea
• Insulin resistance/hyperinsulinaemia
• Ethanol intake of more than 30 g (three standard
drinks) daily
• Anxiety-induced hyperventilation or panic attacks
• Chronic pain
• Intense vasoconstriction (Raynaud’s
phenomenon), arteritis
Identifiable
causes of
hypertension
• Chronic kidney disease
• Renovascular disease
• Primary aldosteronism
• Coarctation
• Cushing’s syndrome
• Phaeochromocytoma
Pseudoresistance • ‘White coat hypertension’ or office elevations
• Pseudohypertension in older patients
• Use of regular cuff in obese patients
Drug-related
causes
• Doses too low
• Wrong type of diuretic
• Inappropriate combinations
• Rapid inactivation (e.g. hydralazine)
Drug actions
and interactions
• Non-steroidal anti-inflammatory drugs (NSAIDs)
• Sympathomimetics: nasal decongestants, appetite
suppressants
• Cocaine, Tik and other recreational drugs
• Oral contraceptives
• Adrenal steroids
• Liquorice (as may be found in chewing tobacco)
• Cyclosporine, tacrolimus, erythropoietin
• Antidepressants (monoamine oxidase inhibitors,
tricyclics)